Spiro-venlafaxine Demethylation Process for High Purity ODV
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing O-desmethyl venlafaxine (ODV) and its pharmaceutical salts face challenges such as unsatisfactory purity and yield, suitability for large-scale production, and the use of hazardous materials, leading to safety and environmental concerns.
Innovation Solution
A process involving the conversion of spiro-venlafaxine hydrochloride to O-desmethyl venlafaxine free base using milder conditions, including the use of alkane thiolate anion and high molecular weight polyol, at elevated temperatures, followed by treatment with paraformaldehyde and formic acid, to achieve higher purity and yield while minimizing impurities and toxic materials.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional demethylation methods using n-butyl lithium or lithium aluminum hydride are used, then O-desmethyl venlafaxine can be produced, but hazardous chemicals are generated requiring high safety measures and making the process unsuitable for large scale production
Solution Approach 1:
The patent changes the chemical parameters by using sodium methoxide as a base and methanol as a solvent instead of n-butyl lithium or lithium aluminum hydride. This parameter change maintains the demethylation function while eliminating hazardous chemicals, making the process safe and suitable for large scale production
Solution Approach 2:
The patent replaces expensive and hazardous reagents (n-butyl lithium, lithium aluminum hydride) with cheaper, safer, and more stable reagents (sodium methoxide, methanol). The new reagents are non-hazardous, inexpensive, and easy to handle, eliminating safety concerns and making the process economically viable for industrial production
2Productivity
If prior art processes are used, then O-desmethyl venlafaxine can be synthesized, but the reaction requires a long period of time to be completed
Solution Approach 1:
The patent optimizes reaction parameters by using methanol as a solvent and sodium methoxide as a base, which creates favorable conditions for rapid demethylation. The elevated temperature (60-100°C) and optimized reagent concentrations accelerate the reaction, reducing completion time from hours to minutes while maintaining high yield and purity
3Manufacturing precision
If conventional reduction conditions are used, then Venlafaxine and ODV can be prepared, but non-satisfactory purity and yield are obtained with significant unwanted by-products
Solution Approach 1:
The patent changes the chemical environment by using methanol as a solvent and sodium methoxide as a base, which provides a controlled and favorable reaction environment. This parameter change selective promotes the desired demethylation reaction while suppressing side reactions, resulting in high purity (≥95% HPLC) and high yield (≥80%) with minimal by-products
Solution Approach 2:
The patent uses methanol as an intermediary solvent that facilitates the demethylation reaction while controlling the reaction environment. Methanol acts as a mediator that allows controlled proton transfer and stabilizes intermediates, leading to selective formation of O-desmethyl venlafaxine with high purity and yield while minimizing unwanted by-products
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process results in a cost-effective, safer, and more environmentally friendly method for producing high-purity O-desmethyl venlafaxine and its salts, suitable for large-scale production, with reduced reaction time and avoidance of hazardous chemicals.
Implementation Method 1
the methyl phenoxy group is very stable against nucleophilic substitution
Implementation Method 2
subsequently treating the reaction mass with paraformaldehyde, formic acid and water at elevated temperature
Data Source
AI summary
The present invention relates to a novel process for the preparation of O-desmethyl venlafaxine (ODV) and the pharmaceutically acceptable salts thereof, wherein it comprises (i) provision of spiro-venlafaxine compound as intermediate; (ii) conversion of spiro-venlafaxine intermediate into ODV free base in a one-pot process; and (iii) optionally conversion ODV free base into pharmaceutically acceptable salts. The present invention further relates to novel processes for the preparation of crystalline salts of ODV-succinate and ODV-oxalate.